Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Combination with Azacitidine (AZA) for Primary Treatment of Int-1, Int-2 and High-Risk Myelodysplastic Syndromes (MDS) Patients with Thrombocytopenia: Outcomes from the Randomized, Placebo-Controlled, Phase III SUPPORT Study May 5, 2017August 13, 2017 liorco70 http://d22fjzb79sfamb.cloudfront.net/MDS2017/fri/1030%20-%201200/Fri%201145.mp4 M. Dickinson (Australia)